Total Payments
$459,782
2024 Payments
$253.43
Companies
17
Transactions
221
Medicare Patients
42
Medicare Billing
$2,507
Payment Breakdown by Category
Research$353,688 (76.9%)
Other$47,850 (10.4%)
Consulting$27,756 (6.0%)
Travel$27,676 (6.0%)
Food & Beverage$2,813 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $353,688 | 49 | 76.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,850 | 15 | 9.8% |
| Consulting Fee | $27,756 | 10 | 6.0% |
| Travel and Lodging | $27,676 | 74 | 6.0% |
| Honoraria | $3,000 | 2 | 0.7% |
| Food and Beverage | $2,813 | 71 | 0.6% |
Payments by Type
Research
$353,688
49 transactions
General
$106,094
172 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $341,334 | 166 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $79,821 | 4 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $28,391 | 11 | $0 (2024) |
| ARBOR PHARMACEUTICALS, INC. | $3,791 | 14 | $0 (2019) |
| Sun Pharmaceutical Industries Inc. | $3,619 | 7 | $0 (2017) |
| Daiichi Sankyo Inc. | $1,800 | 1 | $0 (2017) |
| VERTEX PHARMACEUTICALS INCORPORATED | $379.17 | 1 | $0 (2018) |
| Allergan Inc. | $350.00 | 1 | $0 (2017) |
| Amgen Inc. | $107.26 | 1 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $35.32 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $253.43 | 2 | JAZZ PHARMACEUTICALS INC. ($150.00) |
| 2019 | $35,636 | 29 | Takeda Pharmaceuticals U.S.A., Inc. ($28,287) |
| 2018 | $63,807 | 89 | Jazz Pharmaceuticals Inc. ($44,175) |
| 2017 | $360,085 | 101 | Jazz Pharmaceuticals Inc. ($289,704) |
All Payment Transactions
221 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/03/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 06/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $103.43 | General |
| 09/29/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 09/24/2019 | Shire North American Group Inc | — | Food and Beverage | In-kind items and services | $16.30 | General |
| 08/28/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 08/26/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $11.90 | General |
| Category: Neuroscience | ||||||
| 08/26/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $7.54 | General |
| Category: NEUROLOGY | ||||||
| 08/21/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: NEUROLOGY | ||||||
| 08/19/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $4.24 | General |
| Category: NEUROLOGY | ||||||
| 07/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $925.90 | General |
| 07/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $735.92 | General |
| 07/22/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: NEUROLOGY | ||||||
| 06/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $8,400.00 | General |
| 06/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $850.36 | General |
| 06/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $746.96 | General |
| 06/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | Cash or cash equivalent | $28.30 | General |
| 06/17/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: NEUROLOGY | ||||||
| 06/11/2019 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | Cash or cash equivalent | $84.66 | General |
| 05/24/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: NEUROLOGY | ||||||
| 02/23/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 02/05/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: NEUROLOGY | ||||||
| 02/04/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Travel and Lodging | Cash or cash equivalent | $406.40 | General |
| Category: NEUROLOGY | ||||||
| 01/31/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Travel and Lodging | Cash or cash equivalent | $1,621.03 | General |
| Category: NEUROLOGY | ||||||
| 01/28/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Travel and Lodging | Cash or cash equivalent | $96.30 | General |
| Category: NEUROLOGY | ||||||
| 01/28/2019 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | Cash or cash equivalent | $21.85 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of Xyrem with an open-label pharmacokinetic evaluation and safety extension in pediatric subjects with narcolepsy with cataplexy | Jazz Pharmaceuticals Inc. | $195,010 | 6 |
| Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia | Vanda Pharmaceuticals Inc. | $79,730 | 3 |
| A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $39,558 | 10 |
| A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA | Jazz Pharmaceuticals Inc. | $22,855 | 10 |
| A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $14,121 | 10 |
| DS5565-A-E312 | Daiichi Sankyo Inc. | $1,800 | 1 |
| A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 R-2-amino-3-phenylpropylcarbamate Hydrochloride in Subjects With Parkinson's Disease and Excessive Sleepiness | Jazz Pharmaceuticals Inc. | $533.87 | 8 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia IH With an Open-label Safety Extension | Jazz Pharmaceuticals Inc. | $80.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 42 | 49 | $7,350 | $2,507 |
Total Patients
42
Total Services
49
Medicare Billing
$2,507
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 49 | $7,350 | $2,507 | 34.1% |
About Dr. Todd Swick, MD
Dr. Todd Swick, MD is a Neurology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1730182213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Swick, MD has received a total of $459,782 in payments from pharmaceutical and medical device companies, with $253.43 received in 2024. These payments were reported across 221 transactions from 17 companies. The most common payment nature is "" ($353,688).
As a Medicare-enrolled provider, Swick has provided services to 42 Medicare beneficiaries, totaling 49 services with total Medicare billing of $2,507. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Houston, TX
- Active Since 05/27/2005
- Last Updated 10/05/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1730182213
Products in Payments
- Xyrem (Drug) $267,448
- Hetlioz (Drug) $79,821
- XYREM (Drug) $7,220
- Horizant (Drug) $3,791
- Odomzo (Drug) $3,619
- DS-5565 (Drug) $1,800
- XYWAV (Drug) $150.00
- APTIOM (Drug) $35.32
- BELSOMRA (Drug) $32.68
- TROKENDI XR (Drug) $25.29
- ONFI (Drug) $20.14
- Neupro (Drug) $19.84
- EMGALITY (Drug) $11.90
- AMYVID (Drug) $10.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Houston
William Ondo, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Annette Howard, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Paul Schulz, M.d, M.D
Neurology — Payments: $943,067
Neurology $943,067
Amit Verma, Md, MD
Neurology — Payments: $817,815
Neurology $817,815
Dr. Randolph Evans, Md, MD
Neurology — Payments: $715,948
Neurology $715,948
Dr. John Volpi, Md, MD
Neurology — Payments: $569,676
Neurology $569,676